Slide 1: Cell Therapy Business Entity
Cell Therapy Business Entity April 3rd 2018 Jefferies IO Cell Therapy Summit 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q fil
Slide 3: Bruno Lucidi, CEO AgenTus
Bruno Lucidi, CEO AgenTus • 30 years of industry experience • Founding CEO of Idenix and the Chairman of Pharmasset where he laid the foundation for multi-billion dollar companies (MRK and GILD acquisitions $4bn and $11bn) • Vice President and Head of Pediatric Vaccines at GSK Vaccines (developed $3
Slide 4: Cell therapy business advancing to unlock value
Cell therapy business advancing to unlock value improve body’s existing immune attack on cancer synergistic Immunomodulatory expertise Antibodies Adoptive Cell Therapy* launch rapid immune combination attack against cancer opportunities Cancer Vaccines educate the immune system to see cancer 4 *Prog
Slide 5: Experienced Team
Experienced Team Bruno Lucidi Mark Exley, PhD Cori Gorman, PhD Chief Executive Officer Cellular Immunology Precision Medicine and Manufacturing Developed 6 of Genentech’s drugs >30y drug development leadership Expert cellular immunologist Expert on gene therapy, antibodies, Former founding CEO Ideni
Slide 6: Differentiated cancer cell therapy
Differentiated cancer cell therapy Precision T-Rx Mammalian Display - Direct selection for function Receptors Targets optimal balance between activity and specificity Novel Proprietary target discovery and validation platforms Targets Proprietary Phosphopeptide Tumor Targets Allogeneic Allogeneic ap
Slide 7: Superior receptor discovery through T-Rx platform
Superior receptor discovery through T-RxTM platform Rapid, direct selection for efficacy and specificity Agenus Mammalian Display: Retrocyte DisplayTM and T-RxTM • Agenus mammalian display platform has delivered clinical antibodies currently in Ph1/2 clinical programs* Retroviral transduction Fully
Slide 8: Agenus is the first to discover and characterize fully-human phosphopeptide-specific TCRs
Agenus is the first to discover and characterize fully-human phosphopeptide-specific TCRs Novel Phosphopeptide-Specific TCRs for Cancer Cell Therapy Arthur Hurwitz*, Ekaterina Breous-Nystrom, Alessandra Franchino, Reed Masakayan, Benjamin Wolf, Marco Meier, Sandra Wimberger, Corinne Bouquet, Armen K
Slide 9: Key collaborations with cell therapy experts
Key collaborations with cell therapy experts 9
Slide 10: Portfolio designed for rapid BLA & opportunistic market expansion
Portfolio designed for rapid BLA & opportunistic market expansion Product Disease/Target Partner Preclinical Ph1 Ph2 Ph3 Filed Approved Checkpoint Antibodies AGEN1884 CTLA-4 (antagonist)* next-gen CTLA-4 CTLA-4 (antagonist) Agenus fully-owned programs Partnered programs AGEN2034 PD-1 (antagonist) CD
Slide 11: Team includes renowned experts in I-O R&D and commercialization
Team includes renowned experts in I-O R&D and commercialization Garo Armen, PhD Iman Barilero, PharmD, Ozer Baysal Jennifer Buell, PhD PhD Chief Commercial Officer Chief Communications and Chairman & CEO VP Regulatory Science & and Head of HR External Affairs Officer Pharmacovigilance Elan Corporati
Slide 12: We successfully integrated strategic building blocks
We successfully integrated strategic building blocks Key Acquisitions Platforms/Products • 6 platforms • Aquila (2000) adjuvants • GMP manufacturing • 4-AB (2014) checkpoint • 5 clinical candidates* antibodies Capabilities • PhosImmune (2015) Partnerships novel neoantigens • GlaxoSmithKline • XOMA (
Slide 13: Since entering the I-O space, we have made substantial progress
Since entering the I-O space, we have made substantial progress I-O Capabilities Speed Effective Combinations & Portfolio & Efficiency for Patients 4 Therapeutic modalities CPMs, Vaccines, Cell Therapy*, Adjuvants 5 INDs^ Validated targets filed in 2016 - 2017 CTLA-4 and PD-1 6 Technology platforms
Slide 14: Integrated discovery technologies and immunology expertise
Integrated discovery technologies and immunology expertise Potential for up to 6 new clinical programs in 2 years HIT HIT LEAD CELL LINE ASSET DISCOVERY OPTIMIZATION OPTIMIZATION DEVELOPMENT CTLA-4 next generation Potential Best-in-class TIGIT antagonist Potential Best-in-class CD137 agonist Potenti
Slide 15: Agenus development plan for sustained revenue generation
Agenus development plan for sustained revenue generation ü Develop, register, launch validated CTLA-4 & PD-1 antibodies in 2020 Adoptive cell therapy (CPM/vaccine combo) ü Expand market with novel target combos (Neo-antigen vaccine, TIGIT, CD137) Patient Penetration with Effective Treatments ü Expan
Slide 16: Agenus: driving success in I-O
Agenus: driving success in I-O Record of speed and efficiency in advancing I-O portfolio into clinic Optimal pipeline of leads for effective combinations Enabling partnerships for validated and novel agents Fully integrated capabilities from discovery to GMP manufacturing Separate cell therapy busin